Tevogen Inc. TVGN

Company Overview

Tevogen Bio Holdings Inc. (NASDAQ: TVGN), commonly referred to as Tevogen Inc., is a biotechnology company focused on the development of precision T-cell therapeutics and artificial intelligence-enabled drug discovery platforms. The company operates primarily in the immunotherapy and biotechnology industries, with a strategic emphasis on developing off-the-shelf CD8+ cytotoxic T lymphocyte therapies designed to target infectious diseases and cancers. Its core revenue and value drivers are tied to clinical-stage therapeutic development, intellectual property creation, strategic licensing opportunities, and platform expansion within immunotherapy and AI-enabled healthcare applications.

The company’s lead programs have centered on virus-specific T-cell therapies, particularly for COVID-19 and related infectious disease applications, while it has also expanded its focus toward oncology and broader precision medicine initiatives. Tevogen evolved from a privately developed biotechnology platform into a publicly traded company through a business combination transaction completed in 2024. Public disclosures, including SEC filings, indicate that the company positions itself around scalable cell therapy manufacturing, personalized medicine capabilities, and the integration of AI-driven analytical tools to improve therapeutic discovery and commercialization efficiency.